A prospective observational cohort study was designed.
1. Comparing of the clinical indicators between the hemolytic group and the non-hemolytic group,such as End-tidal carbon monoxide corrected for ambient CO(ETCOc),direct antiglobulin test(DAT), the highest total serum bilirubin level and hemoglobin. To explore the role of ETCOc in the diagnosis of neonatal ABO hemolytic disease. 2. Comparing of the clinical indicators between the neonates with IVIG treatment and the neonates without IVIG treatment in ABO hemolytic disease, such as ETCOc,total serum bilirubin level before IVIG treatment and ETCOc,total serum bilirubin level after IVIG treatment.To explore the clinical value of ETCOc in the treatment of ABO hemolytic disease.
gestational age between 35+0 and 41+6 weeks
birth weight ≥ 2500 grams
respiratory rate < 60 breaths per minute
the neonates admitted to the neonatology department for phototherapy because of hyperbilirubinemia that conforms to the guideline of the experts consensus on the management of neonatal hyperbilirubinemia(2014,in China.)
persistent dyspnea or need for respiratory support
skin damage or structural deformity around the nasal cavity
receive intensive care treatment in the neonatal intensive care unit(NICU)
Severe congenital malformation, chromosomal or genetic abnormality
positive in diagnosis of ABO-HDN
Case-control
Prospective
Not listed
concentration of ETCOc (end tidal carbon monoxide)
ETCOc in ppm
concentration of bilirubin
bilirubin in mg/dl
result of DAT
DAT result of positive or negtive
Click on the lead sponsor to view all of their trials.
